ArticleLung2022

Avanafil as a Novel Therapeutic Agent Against LPS-Induced Acute Lung Injury via Increasing CGMP to Downregulate the TLR4-NF-κB-NLRP3 Inflammasome Signaling Pathway.

Pelin Aydin et al.PubMed ↗Publisher ↗

No numbers read from the abstract.